Neuropharmacology

Article	Citations
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease	388
Mechanisms of action of currently used antiseizure drugs	248
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology	170
Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration	142
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species	131
Inflammation and reactive oxygen species as disease modifiers in epilepsy	113
Amygdala, neuropeptides, and chronic pain-related affective behaviors	105
Central 5-HT receptors and their function; present and future	104
The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments	87
Pharmacoresistance – Epidemiology, mechanisms, and impact on epilepsy treatment	85
The hypocretin (orexin) system: from a neural circuitry perspective	79
Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury	77
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms	74
Social vulnerabilities for substance use: Stressors, socially toxic environments, and discrimination and racism	74
Endogenous opioid peptides in the descending pain modulatory circuit	73
Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model	72
Disease-modifying therapies in amyotrophic lateral sclerosis	71
Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling	68
Biomarkers for epileptogenesis and its treatment	68
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator	65
Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction	64
Sex differences in vulnerability to addiction	62
Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy	60
α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future	59
Progress in nicotinic receptor structural biology	57

Acetylcholinesterase inhibitors (nerve agents) as weapons of mass destruction: History, mechanisms of action, and medical countermeasures	57
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics	57
Optogenetic and chemogenetic therapies for epilepsy	55
Different roles of distinct serotonergic pathways in anxiety-like behavior, antidepressant-like, and anti-impulsive effects	54
Better living through understanding the insula: Why subregions can make all the difference	53
Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model	53
The cannabinoid system and microglia in health and disease	49
The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy	49
Tau immunotherapies: Lessons learned, current status and future considerations	48
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial	47
Astrocyte control of glutamatergic activity: Downstream effects on serotonergic function and emotional behavior	46
Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics	46
NMDA receptors and synaptic plasticity in the anterior cingulate cortex	45
Impulsivity traits and neurocognitive mechanisms conferring vulnerability to substance use disorders	44
Median raphe serotonin neurons promote anxiety-like behavior via inputs to the dorsal hippocampus	43
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research	43
Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics	41
Modifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation	40
Arketamine, a new rapid-acting antidepressant: A historical review and future directions	40
Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/β-catenin signaling in mice	40
Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors	40
AMPA receptor trafficking and LTP: Carboxy-termini, amino-termini and TARPs	40
The tripartite glutamatergic synapse	39
Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA	39
Why we urgently need improved seizure and epilepsy therapies for children and neonates	38
Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening	38
Constitutive activity of 5-HT receptors: Factual analysis	38
Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging	38
Chronic intermittent ethanol exposure dysregulates a GABAergic microcircuit in the bed nucleus of the stria terminalis	38
The role of central amygdala corticotropin-releasing factor in predator odor stress-induced avoidance behavior and escalated alcohol drinking in rats	38
Nose-to-brain delivery of chrysin transfersomal and composite vesicles in doxorubicin-induced cognitive impairment in rats: Insights on formulation, oxidative stress and TLR4/NF-kB/NLRP3 pathways	36
Neurotensin in reward processes	36
Postsynaptic plasticity of GABAergic synapses	36
Inflammation at the crossroads of COVID-19, cognitive deficits and depression	35
Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies	34
Acetylcholinesterase inhibitor exposures as an initiating factor in the development of Gulf War Illness, a chronic neuroimmune disorder in deployed veterans	34
Personalized medicine in genetic epilepsies – possibilities, challenges, and new frontiers	34
Cell biology and dynamics of Neuronal Na+/K+-ATPase in health and diseases	34
Neurobiological mechanisms of early life adversity, blunted stress reactivity and risk for addiction	34
Calpain inhibition ameliorates depression-like behaviors by reducing inflammation and promoting synaptic protein expression in the hippocampus	34
Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease	34
Withdrawal from chronic ethanol exposure increases postsynaptic glutamate function of insular cortex projections to the rat basolateral amygdala	33
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin	33
Long-term effects of maternal cannabis vapor exposure on emotional reactivity, social behavior, and behavioral flexibility in offspring	33
Caffeic acid phenethyl ester counteracts doxorubicin-induced chemobrain in Sprague-Dawley rats: Emphasis on the modulation of oxidative stress and neuroinflammation	33
Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression	33
GABAAR isoform and subunit structural motifs determine synaptic and extrasynaptic receptor localisation	33
Loss of vagal integrity disrupts immune components of the microbiota-gut-brain axis and inhibits the effect of Lactobacillus rhamnosus on behavior and the corticosterone stress response	33
Evolution of glutamatergic signaling and synapses	33
Endocannabinoids, cannabinoids and the regulation of anxiety	33

Sex differences in pain along the neuraxis	32
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders	32
5-aminolevulinic acid inhibits oxidative stress and ameliorates autistic-like behaviors in prenatal valproic acid-exposed rats	32
No prevention or cure of epilepsy as yet	32
Contrasting sex-dependent adaptations to synaptic physiology and membrane properties of prefrontal cortex interneuron subtypes in a mouse model of binge drinking	32
The vagus nerve is necessary for the rapid and widespread neuronal activation in the brain following oral administration of psychoactive bacteria	31
Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: A role of gut microbiota	31
Ketamine and its metabolites: Potential as novel treatments for depression	31
TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders	31
Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors	31
Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1−42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease	31
Modifying genetic epilepsies – Results from studies on tuberous sclerosis complex	31
CNS pharmacology of NKCC1 inhibitors	31
Promising vulnerability markers of substance use and misuse: A review of human neurobehavioral studies	31
How does the skeletal muscle communicate with the brain in health and disease?	31
Why we urgently need improved epilepsy therapies for adult patients	30
Lithium enhances post-stroke blood-brain barrier integrity, activates the MAPK/ERK1/2 pathway and alters immune cell migration in mice	30
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets	30
Organ and brain crosstalk: The liver-brain axis in gastrointestinal, liver, and pancreatic diseases	29
BET bromodomains as novel epigenetic targets for brain health and disease	29
Need for speed: Super-resolving the dynamic nanoclustering of syntaxin-1 at exocytic fusion sites	29
The 5-HT6 receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies	28
Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease	28
Increased dopamine transmission and adult neurogenesis in trace amine-associated receptor 5 (TAAR5) knockout mice	28
Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving	27
Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs	27
Interactions between the microbiota and enteric nervous system during gut-brain disorders	27
Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration	26
Protective effect of sodium propionate in Aβ1-42 -induced neurotoxicity and spinal cord trauma	26
GRP receptor and AMPA receptor cooperatively regulate itch-responsive neurons in the spinal dorsal horn	26
Nucleus accumbens melanin-concentrating hormone signaling promotes feeding in a sex-specific manner	26
Oral glutathione administration inhibits the oxidative stress and the inflammatory responses in AppNL−G-F/NL−G-F knock-in mice	26
Dynamic compartmentalization of calcium channel signalling in neurons	26
Metformin attenuates cadmium-induced neuronal apoptosis in vitro via blocking ROS-dependent PP5/AMPK-JNK signaling pathway	26
Neurogenesis after traumatic brain injury - The complex role of HMGB1 and neuroinflammation	25
The role of the excitation:inhibition functional balance in the mPFC in the onset of antidepressants	25
Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors	25
The Sigma-2 receptor / transmembrane protein 97 (σ2R/TMEM97) modulator JVW-1034 reduces heavy alcohol drinking and associated pain states in male mice	25
Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model	25
Molecular and neuronal mechanisms underlying the effects of adolescent nicotine exposure on anxiety and mood disorders	25
Astrocytes in rapid ketamine antidepressant action	25
Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1α/Nrf2/HO-1 pathway in ALS mice	25
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery	25
N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain	25
PACAP regulation of central amygdala GABAergic synapses is altered by restraint stress	25
Cannabidiol anticonvulsant effect is mediated by the PI3Kγ pathway	25
Genetic causes of PD: A pathway to disease modification	24
History repeats itself: Role of characterizing flavors on nicotine use and abuse	24
A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice	24
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease	24
Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats	24
Chronic brain histamine depletion in adult mice induced depression-like behaviours and impaired sleep-wake cycle	24
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis	24
Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice	23
Female and male rats readily consume and prefer oxycodone to water in a chronic, continuous access, two-bottle oral voluntary paradigm	23
Astrocytes and major depression: The purinergic avenue	23
Endothelin receptor antagonists alleviate blood-brain barrier disruption and cerebral edema in a mouse model of traumatic brain injury: A comparison between bosentan and ambrisentan	23
Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy	23
Glutamate transporters: Critical components of glutamatergic transmission	23
Comparative profile of refractory status epilepticus models following exposure of cholinergic agents pilocarpine, DFP, and soman	23
CB1R-dependent regulation of astrocyte physiology and astrocyte-neuron interactions	23
Chronic social isolation exerts opposing sex-specific consequences on serotonin neuronal excitability and behaviour	23
Kainate receptors and synaptic plasticity	23
Targeting the 5-HT system: Potential side effects	22
Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders	22
Activation of TREM2 attenuates neuroinflammation via PI3K/Akt signaling pathway to improve postoperative cognitive dysfunction in mice	22
Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs	22
Membrane trafficking and positioning of mGluRs at presynaptic and postsynaptic sites of excitatory synapses	22
Protein-protein interactions at the NMDA receptor complex: From synaptic retention to synaptonuclear protein messengers	22
New hopes for disease modification in Parkinson's Disease	22
A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model	22
Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg	22
In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45	22
Hippocampal synaptic dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A2AR blockade	22
Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation?	22
Glucocorticoid receptor modulators decrease alcohol self-administration in male rats	22
Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice	22
Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions	22
TRPV4 inhibitor HC067047 produces antidepressant-like effect in LPS-induced depression mouse model	22
Mechanisms of endocannabinoid control of synaptic plasticity	21

Social dysfunction in the neurodevelopmental model of schizophrenia in male and female rats: Behavioural and biochemical studies	21
The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse	21
Optogenetic manipulations of CeA-CRF neurons modulate pain- and anxiety-like behaviors in neuropathic pain and control rats	21
Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum	21
In vivo imaging of alpha-synuclein with antibody-based PET	21
Contributions of neuroimmune and gut-brain signaling to vulnerability of developing substance use disorders	21
Lactate enhances Arc/arg3.1 expression through hydroxycarboxylic acid receptor 1-β-arrestin2 pathway in astrocytes	21
Approved cannabinoids for medical purposes – Comparative systematic review and meta-analysis for sleep and appetite	21
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD)	21
Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex	21
Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT4 receptors and cAMP-dependent mechanisms	21
Novel ethical and policy issues in psychiatric uses of psychedelic substances	21
Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias	20
Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones	20
Trans-synaptic LGI1–ADAM22–MAGUK in AMPA and NMDA receptor regulation	20
Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease	20
Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus c	20
Gestational exposures to organophosphorus insecticides: From acute poisoning to developmental neurotoxicity	20
The rostromedial tegmental (RMTg) “brake” on dopamine and behavior: A decade of progress but also much unfinished work	20
Sevoflurane depresses neurons in the medial parabrachial nucleus by potentiating postsynaptic GABAA receptors and background potassium channels	20
Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice	20
The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation	20
Rescue of ethanol-induced FASD-like phenotypes via prenatal co-administration of choline	20
Effects of 5-HT2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour	20
Existence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillations	20
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease	20
Treatment of acetylcholinesterase inhibitor-induced seizures with polytherapy targeting GABA and glutamate receptors	20
SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain	20
Sex differences in fear responses: Neural circuits	19
Apoptosis-triggered decline in hippocampal microglia mediates adolescent intermittent alcohol exposure-induced depression-like behaviors in mice	19
Glycine agonism in ionotropic glutamate receptors	19
A bibliometric analysis of research on (R)-ketamine from 2002 to 2021	19
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care	19
Psychedelics therapeutics: What we know, what we think, and what we need to research	19
Brain insulin action: Implications for the treatment of schizophrenia	19
A novel biscoumarin compound ameliorates cerebral ischemia reperfusion-induced mitochondrial oxidative injury via Nrf2/Keap1/ARE signaling	19
Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases	19
Noradrenergic circuits and signaling in substance use disorders	19
Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite	19
Extracellular ATP: A powerful inflammatory mediator in the central nervous system	19
GluA1-homomeric AMPA receptor in synaptic plasticity and neurological diseases	19
Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers	19
Fractional occupancy of synaptic binding sites and the molecular plasticity of inhibitory synapses	19
Exogenous microbiota-derived metabolite trimethylamine N-oxide treatment alters social behaviors: Involvement of hippocampal metabolic adaptation	19
Slow-binding inhibitors of acetylcholinesterase of medical interest	19
Effect of early life social adversity on drug abuse vulnerability: Focus on corticotropin-releasing factor and oxytocin	19
NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia	19
Enhanced white matter reorganization and activated brain glucose metabolism by enriched environment following ischemic stroke: Micro PET/CT and MRI study	19
Surface trafficking of neurotransmitter receptors: From cultured neurons to intact brain preparations	19
Seizure-induced neuroinflammation contributes to ectopic neurogenesis and aggressive behavior in pilocarpine-induced status epilepticus mice	18
Activation of adenosine A2A receptors in the olfactory tubercle promotes sleep in rodents	18
Glutamate receptors and synaptic plasticity: The impact of Evans and Watkins	18
Ventral tegmental area GABAergic neurons induce anxiety-like behaviors and promote palatable food intake	18
Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain	18
Src and Fyn regulation of NMDA receptors in health and disease	18
SARS-CoV-2-associated cytokine storm during pregnancy as a possible risk factor for neuropsychiatric disorder development in post-pandemic infants	18
Sex differences in corticotropin releasing factor peptide regulation of inhibitory control and excitability in central amygdala corticotropin releasing factor receptor 1-neurons	18
Adolescent cannabis exposure increases heroin reinforcement in rats genetically vulnerable to addiction	18
Non-mitogenic fibroblast growth factor 1 protects against ischemic stroke by regulating microglia/macrophage polarization through Nrf2 and NF-κB pathways	18
Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum	18
Regulation and dysregulation of neuronal circuits by KARs	18
KCC2 membrane diffusion tunes neuronal chloride homeostasis	18
Ketamine activated glutamatergic neurotransmission by GABAergic disinhibition in the medial prefrontal cortex	18
Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration	18
Ketamine; history and role in anesthetic pharmacology	18
A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders	18
Molecular, biochemical and behavioural evidence for a novel oxytocin receptor and serotonin 2C receptor heterocomplex	18
The role of CaMKII autophosphorylation for NMDA receptor-dependent synaptic potentiation	18
Danger and distress: Parabrachial-extended amygdala circuits	17
mGluR1 signaling in cerebellar Purkinje cells: Subcellular organization and involvement in cerebellar function and disease	17
Dysregulation of behavioral and autonomic responses to emotional and social stimuli following bidirectional pharmacological manipulation of the basolateral amygdala in macaques	17
Oxytocin in the neural control of eating: At the crossroad between homeostatic and non-homeostatic signals	17
NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism	17
Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism	17
The feast and famine: Epilepsy treatment and treatment gaps in early 21st century	17
Seizure prediction and intervention	17
Inhibiting the interaction between apoptosis-inducing factor and cyclophilin A prevents brain injury in neonatal mice after hypoxia-ischemia	17
Pharmacological inhibition of the cGAS-STING signaling pathway suppresses microglial M1-polarization in the spinal cord and attenuates neuropathic pain	17
Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal	17
Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota	17
RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer's disease	17
The crosstalk between brain and periphery: Implications for brain health and disease	17
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine	17
Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators	17
Maresin 2 is an analgesic specialized pro-resolution lipid mediator in mice by inhibiting neutrophil and monocyte recruitment, nociceptor neuron TRPV1 and TRPA1 activation, and CGRP release	17
Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction	17
Common cellular and molecular mechanisms and interactions between microglial activation and aberrant neuroplasticity in depression	17
Adolescent intermittent ethanol (AIE) produces sex specific alterations in adult neuroimmune gene expression and ethanol sensitivity that are independent of ethanol metabolism	17
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment	16
Female but not male rats show biphasic effects of low doses of Δ9-tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?	16
Alcohol drinking during early adolescence activates microglial cells and increases frontolimbic Interleukin-1 beta and Toll-like receptor 4 gene expression, with heightened sensitivity in male rats co	16
Hemopressin as a breakthrough for the cannabinoid field	16
Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats	16
Differential glutamatergic and GABAergic contributions to the tetrad effects of Δ9-tetrahydrocannabinol revealed by cell-type-specific reconstitution of the CB1 receptor	16
Covid-19 interface with drug misuse and substance use disorders	16